Current research at Weill Cornell and the New York Genome Center
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
Why the rapid development of new drugs poses new challenges
The aims of the Genomics England CLL pilot